Product Description
AMG 211 is a bispecific CEA-directed CD3 T-cell engager (BiTE(R)) that inhibits growth of CEA-expressing cancer cells in various cancer models. (Sourced from: https://www.annalsofoncology.org/article/S0923-7534(19)48893-5/fulltext)
Mechanisms of Action: CEA Inhibitor, CD3 Inhibitor
Novel Mechanism: Yes
Modality: Bispecific Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Adenocarcinoma
Phase 1: Adenocarcinoma|Gastrointestinal Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02291614 |
NCT02291614 | P1 |
Terminated |
Adenocarcinoma |
2017-11-06 |
2021-03-17 |
||
NCT02760199 |
NCT02760199 | P1 |
Completed |
Gastrointestinal Cancer |
2017-05-03 |
2019-03-20 |
||
NCT01284231 |
MI-CP216 | P1 |
Completed |
Adenocarcinoma |
2015-01-01 |
2019-03-19 |
||
2015-004370-14 |
89Zr-AMG211 PET imaging study | P2 |
Terminated |
Adenocarcinoma |
2017-07-07 |
2022-03-13 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|